Dopamine analog amide

Details Dopamine analog amide Dopamine analog amide

1995-06-06

2000-08-22

Carr, Deborah D

Organic compounds -- part of the class 532-570 series

Organic compounds

Fatty compounds having an acid moiety which contains the...

554223, 554224, 564204, 564207, 560144, 560163, 514 2, 514 17, 514284, 514400, 514415, 514629, 514849, 548342, 548504, 548507, 530303, 530322, C07F 902

Patent

active

061074993

ABSTRACT:
The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug.
In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

REFERENCES:
patent: 3539573 (1970-11-01), Schmutz et al.
patent: 4088646 (1978-05-01), Ishida et al.
patent: 4346085 (1982-08-01), Growdon et al.
patent: 4351831 (1982-09-01), Growden et al.
patent: 4550109 (1985-10-01), Folkers et al.
patent: 4554272 (1985-11-01), Bock et al.
patent: 4558049 (1985-12-01), Bernardi et al.
patent: 4636494 (1987-01-01), Growdon et al.
patent: 4684646 (1987-08-01), Chang et al.
patent: 4692441 (1987-09-01), Alexander et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4933324 (1990-06-01), Shashoua
patent: 4939174 (1990-07-01), Shashoua
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 5112863 (1992-05-01), Hashimoto et al.
patent: 5214062 (1993-05-01), Mark et al.
patent: 5284876 (1994-02-01), Shashoua et al.
patent: 5308832 (1994-05-01), Garleb et al.
patent: 5466841 (1995-11-01), Horrobin et al.
patent: 5532374 (1996-07-01), Lee et al.
patent: 5545719 (1996-08-01), Shashaoua
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5604216 (1997-02-01), Horrobin
patent: 5646180 (1997-07-01), Chaturvedi
patent: 5654290 (1997-08-01), Bayon et al.
patent: 5750572 (1998-05-01), Bruzzese
Iwakami et al., Chem. Pharm. Bull. 34(9), pp. 3960-3963, 1986.
Chem. abstr. vol. 106, No. 12, p. 363, col. 2, abstract No. 90177x, 1987.
Schabitz, WR, et al., "The Effects of prolonged treatement with . . . ", J. Neurol. Sci. 138:1-2:21-25 (1996).
D'Orlando KJ, et al., "Citicoline (CDP-Choline); Mechanisms of . . . " Neurol. Res., 17:4:281-284 (1995).
Nishio K., et al., "Novel Water-Soluble Derivatives . . . ", Proc. Soc. Exp. Biol. Med., 203:2:200-208 (1993).
Jacob, J.N. et al., "Gamma-aminobutyric acid esters. 3. Synthesis, brain uptake, and pharmacological properties of C-18 Glyceryl lipid esters of GABA with varying degree of unsaturation," J. Med. Chem. 30:1573-6 (1987).
Hesse, G.W. et al., "Uptake in brain and neurophysiological activity of two lipid esters of gamma-aminobutyric acid," Neuropharmacol. 27:637-40 (1988).
Jacob, J.N. et al., "Synthesis, brain uptake and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor, gamma-vinyl-GABA," J. Med. Chem. 33:733-6 (1990).
Ferrari et al., 9-cis-6,6'-diapo-.gamma., .gamma.-carotenedioic acid derivatives and pharmaceutical compositions containing them, p. 710 Abstract No. 20423w, Chemical Abstracts 95(23) issued Dec. 7, 1981, EP30,009 dated Jun. 10, 1981.
T. Higuchi et al., "Prodrugs as Novel Drug Delivery Systems", American Chem. Society, ACS Symposium Series, vol. 14, pp. 14-15 (1975).
S. Iwakami et al., "Inhibition of Arachidonate 5-Lipoxygenase by Phenolic Compounds", Chem. Pharm. Bull. (Japan), 34(9), 3960-3963,1986.
Y. Makino et al., Chemical Abstracts, vol. 106, No. 12, issued 23 Mar. 1987, "Pharmaceuticals Permeable to Blood-Brain Barrier", p. 363, Abstract No. 90177x, Japan Kokai Tokyo Koho, JP61,204,136, dated Sep. 10, 1986.
G. Dhopeshwarker, Chemical Abstracts, vol. 76, No. 16, issued Apr. 17, 1972, "Fatty Acid Transport Into the Brain", p. 276, Abstract No. 97365c, Biochim Biophys. Acta 1972, 255(2) 572-9.
R. Spector, Chemical Abstracts, vol. 108, No. 11, issued Mar. 14, 1988, "Fatty Acid Transport Through the Blood-Brain Barrier", p. 435, Abstract No. 92100q, J. Neurochem. 1988, 50(2), 639-43.
I. Yamatsu et al., Chemical Abstracts, vol. 100, No. 19, issued May 7, 1984, "Polyprenyl Carboxylic Acid Amides", p. 555, Abstract No. 156839z, EP91,694 dated Oct. 19, 1983.
V.E. Shashoua, et al., ".gamma.-Aminobutyric Acid Esters.1. Synthesis . . . ", Journal of Medicinal Chemistry, vol. 27, No. 5, pp. 659-664 (1984).
J.N. Jacob, et al., ".gamma.-Aminobutyric Acid Esters.2.Synthesis Brain Uptake . . . ", J. of Medicinal Chemistry, vol.28, No.1, pp. 106-110 (1985).
G.W. Hesse et al., "Inhibitory Effect of Cholesteryl.gamma.-Aminobutyrate" Neurolpharmacology, vol. 24, No. 2, pp. 139-146 (1985).
G. Bourat et al., "Long Chain Esters of Pipotiazine as Long-Acting Psychotropic Pro-Drugs", pp. 105-114, (1976) Med. Chem. Proc. Int. Symp. 5th.
K.A. Jacobson et al., "Adenosine analogs with covalently attached lipids . . . ", FEBS Letters, vol.225, Nos.1,2 pp. 97-102 (Dec. 1987).
A. Garzon-Aburbeh et al., "A Lymphotropic Prodrug of L-Dopa:Synthesis" J. Med. Chem. 29: 687-691 (1986).
U.K. Mazumdar & D.C. Dey, "Preparation and Evaluation of Ethambutol Derivatives", Indian J. Pharm. Sci. 47(6): 179-180 (1984).
L.M. Gunne et al., "Oral Dyskinesia in Rats Following Brain Lesions and Neuroleptic Drug Administration", Psychopharmacology 77:134-9 1982.
R.J. Baldessarini et al., "Dopamine and the Pathophysiology of Dyskinesis . . . ", Ann. Rev. Neurosci. 3: 23-41 (1980).
J.P. Lohr et al., "Neuroleptic-Induced Movement Disorders . . . ", Psychiatry, vol. 3, (1989).
Jacob, J.N. et al., "Gamma-aminobutyric acid esters. 3. Synthesis, brain uptake, and pharmacological properties of C-18 Glyceryl lipid esters of GABA with varying degree of unsaturation," J. Med. Chem. 30:1573-6 (1987).
Hesse, G.W. et al., "Uptake in brain and neurophysiological activity of two lipid esters of gamma-aminobutyric acid," Neuropharmacol. 27:637-40 (1988).
Jacob, J.N. et al., "Synthesis, brain uptake and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor, gamma-vinyl-GABA," J. Med. Chem. 33:733-6 (1990).
T. Higuchi, et al., ACS Symposium Series, vol. 14, see pp. 14 and 15.
S. Iwakami, et al., Chem. Pharm. Bull. (Japan), 34(9), 3960-3963 (Sep., 1986).
Y. Makino, et al., Abstract No. 90177x, vol. 106, Sep. 10, 1986.
G. Dhopeshwarkar, et al., Abstract No. 97365c, vol. 76, Apr. 17, 1972.
R. Spector, Abstract No. 92100g, vol. 108, Mar. 14, 1988.
Yamatsu, et al., Abstract No. 156839z, vol. 100, May 7, 1984.
V.E Shashoua, et al. Journal of Medicinal Chemistry, vol. 27, No. 5 pp. 659-664 (1984).
J.N. Jacob, et al., Journal of Medicinal Chemistry, vol. 28, No. 1, pp. 106-110 (1985).
G.W. Hesse, et al., Neurolpharmacology, vol. 24, No. 2, pp. 139-146 (1985).
G. Bourat and D. Heusse, "Long Chain Esters of Pipotiazine as Long-Acting Psychotropic Pro-Drugs", Med. Chem. Pro. Intl. Symp. 5th (1976), pp. 105-114.
K.A. Jacobson et al., "Adenosine analogs with covalently attached lipids . . . ", FEBS Letters, vol.225, Nos.1, 2 pp. 97-102 (Dec.1987).
A. Garzon-Aburheh et al., "A Lymphotropic Prodrug of L-Dopa: Synthesis Pharmacological . . . ", J.Med.Chem. 29: 687-691 (1986).
U.K. Mazumdar et al., "Preparation and Evaluation of Ethambutol Derivatives", Indian J. Pharm. Sci. 47(6): 179-180 (1985).
L.M. Gunne et al., "Oral Dyskinesia in Rats Following Brain Lesions . . . ", Psychopharmacology 77: 134-139 (1982).
R.J. Baldessarini et al., "Dopamine and the Pathophysiology of Dyskinesias . . . ", Ann. Rev. Neurosci. 3: 23-41 (1980).
J.P. Lohr et al., "Neuroleptic-Induced Movement Disorders: Tarvide Dyskinesia and Other Tarvide Syndromes", Psychiatry, vol.3, 1989.
Bauret et al, Med. Chem. Proc. Int. Symp., pp. 105-114, 1976.
Iwakami et al, Chem. Pharm. Bull. (Japan), 34(a),3960-3963, 1980.

Affiliated with

Also associated with

Rating

Dopamine analog amide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dopamine analog amide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine analog amide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-582826